Credit Suisse Starts AC Immune SA (ACIU) at Outperform
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Credit Suisse initiates coverage on AC Immune SA (NASDAQ: ACIU) with a Outperform rating and a price target of $18.00.
Analyst Alethia Young commented, "AC Immune is focused on neurodegenerative diseases, primarily Alzheimer’s Disease (AD). Their lead asset, crenezumab, is in Phase 3 in partnership with Roche. AC Immune is developing more than just crenezumab which allows for some optionality with early AD targets like Tau or AD vaccines. In this report, we will focus on near-term catalyst which will be a stock read-through from a competitive Phase 3 program being developed by Lilly. We view this story as high risk/high reward in the nearterm. In the long-term post the headline risk, we are positive for 3 reasons: 1) no AD asset is exactly the same and designs differ so it will be uncertain that if solanezumab (Sola) fails all drugs fail, 2) their Ph3 and Biogen's (another competitor) will continue even if Lilly is a complete fail, and 3) AC Immune has other assets that could be used in combination or separately from crenezumab."
Shares of AC Immune SA closed at $14.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Upgrades CVR Refining (CVRR) to Outperform; Most Exposed to RINs
- MKM Partners Raises Price Target on Broadcom Ltd. (AVGO) to $207 Following 4Q Beat
- Jefferies Raises Price Target on Finisar (FNSR) to $37 Following 2Q Beat and Raise
Create E-mail Alert Related CategoriesAnalyst Comments, Hot New Coverage, New Coverage
Related EntitiesCredit Suisse
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!